Pan-KRAS Inhibitor BGB-53038

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BGB-53038 selectively targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis. BGB-53038 has only weak inhibitory activity against NRAS and HRAS, which may reduce the risk of side effects.

**Synonyms:** - BGB 53038 - BGB-53038 - BGB53038 - KRAS Inhibitor BGB-53038 - KRAS Mutant-selective Inhibitor BGB-53038 - Pan-KRAS Mutant Inhibitor BGB-53038